Shares of Roivant Sciences Ltd. (NASDAQ:ROIV – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $17.39.
ROIV has been the topic of several research analyst reports. HC Wainwright reiterated a “buy” rating and issued a $18.00 price objective on shares of Roivant Sciences in a report on Thursday, September 19th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Roivant Sciences in a report on Thursday, September 19th. Piper Sandler lifted their price objective on Roivant Sciences from $20.00 to $22.00 and gave the stock an “overweight” rating in a report on Wednesday, July 10th. Finally, Bank of America lifted their price objective on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th.
Insider Activity
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. nVerses Capital LLC purchased a new position in Roivant Sciences in the second quarter worth approximately $34,000. Point72 Hong Kong Ltd purchased a new position in shares of Roivant Sciences during the second quarter worth $36,000. Quarry LP purchased a new position in shares of Roivant Sciences during the second quarter worth $53,000. Acadian Asset Management LLC purchased a new position in shares of Roivant Sciences during the first quarter worth $72,000. Finally, Fifth Third Wealth Advisors LLC purchased a new position in shares of Roivant Sciences during the second quarter worth $101,000. 64.76% of the stock is currently owned by hedge funds and other institutional investors.
Roivant Sciences Price Performance
NASDAQ:ROIV opened at $11.80 on Friday. Roivant Sciences has a 52 week low of $8.24 and a 52 week high of $13.06. The company has a quick ratio of 27.91, a current ratio of 27.91 and a debt-to-equity ratio of 0.05. The stock has a market capitalization of $8.72 billion, a PE ratio of 2.33 and a beta of 1.24. The stock’s 50-day moving average price is $11.80 and its 200-day moving average price is $11.23.
Roivant Sciences (NASDAQ:ROIV – Get Free Report) last posted its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a negative return on equity of 17.23% and a net margin of 2,991.75%. The firm had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. During the same period last year, the firm earned ($0.38) EPS. The company’s quarterly revenue was up 155.1% on a year-over-year basis. As a group, equities analysts expect that Roivant Sciences will post -1.14 EPS for the current fiscal year.
About Roivant Sciences
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading
- Five stocks we like better than Roivant Sciences
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Why Meta’s Pre-Earnings Dip Could Be A Golden Entry Opportunity
- Do ETFs Pay Dividends? What You Need to Know
- Spirit Airlines Stock Nearly Doubled: Are Clear Skies Ahead?
- What Does a Stock Split Mean?
- Tesla Stock: Buy the Dips, Sell the Rips
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.